ACROBiosystems is pleased to announce a supply agreement with PATH, a non-profit global health organization in order to support PATH’s development of a critically needed COVID-19 Diagnostics Benchmarking Panel with which to effectively compare the analytical performance of commercially available antigen-based rapid diagnostic tests (RDTs).

ACROBiosystems will provide PATH with high quality COVID-19 nucleocapsid and/or Spike reference proteins, that will be used to support development of a PATH COVID-19 Diagnostics Benchmarking Panel. The PATH COVID-19 diagnostic benchmarking panel is an exportable set of “blinded” components that enables an unbiased evaluation of the analytical performance antigen RDTs. The components include panel diluent controls, a range of concentrations of inactivated SARS-CoV-2 virus and recombinant SARS-CoV-2 N protein antigens, SARS-CoV-2 negative nasal eluate, and other human common coronaviruses.

“We highly respect the contributions that PATH has made to support the development of COVID-19 diagnostics during the pandemic, Mike Chen, the President & CEO of ACROBiosystems said, “ACROBiosystems has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published. Through a collaboration with PATH, the development of RDTs for COVID-19 could further accelerate strategic response efforts.

Find out more critical reagents for COVID-19 diagnostics

ACROBiosystems Inc.

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostics. The team has established long-term collaborations with big pharms, such as Pfizer, Novartis, and Johnson & Johnson, and well-known academic institutes.

To fight against COVID-19, ACROBiosystems has developed high-quality super stable trimeric S protein, S RBD, S1, S2, and N proteins, paired antibodies with outstanding sensitivity verified by inactivated virus samples and featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection to accelerate the vaccine development.

PATH

PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. Our team of innovators comprises 1,400+ employees in offices in 20 countries. With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions—including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide. We work in more than 70 countries to transform bold ideas into sustainable solutions that improve health and well-being for all, reaching more than 150 million people, on average, each year.